Lecanemab in the treatment of early Alzheimer’s disease – a review of the literature

Wiktor Szymajda; Łukasz Salamaga; Weronika Skoczek; Bartosz Zaleski; Mikołaj Araszewski; Ada Kaczmarek; Grzegorz Kolasa

doi:10.5114/fpn.2024.140847

eISSN: 2449-9315
ISSN: 1234-8279

Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

Open access

1/2024
vol. 40

Send email

Copy url:

abstract:

Review article

Lecanemab in the treatment of early Alzheimer’s disease – a review of the literature

Wiktor Szymajda

¹

,

Łukasz Salamaga

¹

,

Weronika Skoczek

¹

,

Bartosz Zaleski

¹

,

Mikołaj Araszewski

¹

,

Ada Kaczmarek

^{1, 2}

,

Grzegorz Kolasa

²

Faculty of Medicine, Poznan University of Medical Sciences, Poznan, Poland
Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland

Farmakoterapia w Psychiatrii i Neurologii 2024, 40 (1), 31–42

DOI: https://doi.org/10.5114/fpn.2024.140847

Online publish date: 2024/08/01

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Szymajda W, Salamaga Ł, Skoczek W, et al. Lecanemab in the treatment of early Alzheimer’s disease – a review of the literature. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii. 2024;40(1):31-42. doi:10.5114/fpn.2024.140847.

APA

Szymajda, W., Salamaga, Ł., Skoczek, W., Zaleski, B., Araszewski, M.,  & Kaczmarek, A. et al. (2024). Lecanemab in the treatment of early Alzheimer’s disease – a review of the literature. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, 40(1), 31-42. https://doi.org/10.5114/fpn.2024.140847

Chicago

Szymajda, Wiktor, Łukasz Salamaga, Weronika Skoczek, Bartosz Zaleski, Mikołaj Araszewski, Ada Kaczmarek,  and Grzegorz Kolasa. 2024. "Lecanemab in the treatment of early Alzheimer’s disease – a review of the literature". Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii 40 (1): 31-42. doi:10.5114/fpn.2024.140847.

Harvard

Szymajda, W., Salamaga, Ł., Skoczek, W., Zaleski, B., Araszewski, M., Kaczmarek, A.,  and Kolasa, G. (2024). Lecanemab in the treatment of early Alzheimer’s disease – a review of the literature. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, 40(1), pp.31-42. https://doi.org/10.5114/fpn.2024.140847

MLA

Szymajda, Wiktor et al. "Lecanemab in the treatment of early Alzheimer’s disease – a review of the literature." Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii, vol. 40, no. 1, 2024, pp. 31-42. doi:10.5114/fpn.2024.140847.

Vancouver

Szymajda W, Salamaga Ł, Skoczek W, Zaleski B, Araszewski M, Kaczmarek A et al. Lecanemab in the treatment of early Alzheimer’s disease – a review of the literature. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii. 2024;40(1):31-42. doi:10.5114/fpn.2024.140847.

PlumX metrics:

Objectives.
Alzheimer’s disease (AD) is a neurodegenerative disorder that causes cognitive decline and memory loss due to protein accumulation in the brain. Current pharmacological treatments like cholinesterase inhibitors and memantine have limitations, so there is a need for new therapies. Lecanemab is a monoclonal antibody that targets a specific form of amyloid-beta (Aβ) in the brain. It has shown promise in slowing down the progression of AD and protecting neurons. However, it has been associated with the incidence of adverse events in clinical trials, including infusion-related reactions (IRRs) and amyloid-related imaging abnormalities (ARIA). This review includes up-to-date publications concerning the efficacy of lecanemab in the treatment of AD. The characteristics of lecanemab and its precise mechanism of action were presented. The adverse reactions were likewise discussed.

Literature review.
The phase II clinical trial “201” and the phase III “Clarity AD” trial assessed the safety and efficacy of lecanemab. The Study “201” identified the optimal dosage (10 mg/kg biweekly) of lecanemab to achieve maximum treatment effect and showed a 30% less clinical decline compared to placebo. The “Clarity AD” study showed significant differences between patients taking lecanemab and those taking a placebo, using the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and changes in Aβ volume on PET as primary endpoints.

Conclusions.
Lecanemab represents a promising new therapeutic option for individuals with AD, but ongoing research is needed to determine its long-term efficacy and safety.

keywords:

Lecanemab in the treatment of early Alzheimer’s disease – a review of the literature

Wiktor Szymajda 1 , Łukasz Salamaga 1 , Weronika Skoczek 1 , Bartosz Zaleski 1 , Mikołaj Araszewski 1 , Ada Kaczmarek 1, 2 , Grzegorz Kolasa 2

Alzheimer’s disease, lecanemab, amyloid beta, amyloid-related imaging abnormalities (ARIA)

Wiktor Szymajda

¹

,

Łukasz Salamaga

¹

,

Weronika Skoczek

¹

,

Bartosz Zaleski

¹

,

Mikołaj Araszewski

¹

,

Ada Kaczmarek

^{1, 2}

,

Grzegorz Kolasa

²